Cowen analyst Boris Peaker said Clearside Biomedical (NASDAQ: CLSD) overreacted to DME data and has positive catalysts ahead.Peaker commented, "Clearside's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE